Minapharm finalises Probiogen acquisition

Egyptian pharmaceutical company Minapharm has completed the acquisition of 95 per cent of the share capital of Probiogen, a German cell-line development and contract manufacturing specialist, for €30.4m (£25.3m).

Probiogen will continue to be a technology and service provider for its global biopharmaceutical clients.